

# European Journal of Immunology

Supporting Information  
for

**DOI 10.1002/eji.201646898**

Hayden Pearce, Paul Hutton, Shalini Chaudhri, Emilio Porfiri, Prashant Patel,  
Richard Viney and Paul Moss

**Spontaneous CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses directed against cancer testis  
antigens are present in the peripheral blood of testicular cancer patients**

Supplementary Table. 1 Patient characteristics

		Frequency (number)	
<b>Tumour subtype</b>	All subtypes	100% (72)	
	Seminoma	66% (48)	
	NSGCTT	20% (14)	
	mGCT	14% (10)	
<b>Tumour stage</b>	Seminoma	Stage 1	81% (39)
		Stage 2a	6% (3)
		Stage 2b	11% (5)
		Stage 3	2% (1)
	NSGCTT	Stage 1 (localised)	36% (5)
		LVI -	40% (2)
		LVI +	60% (3)
		Stage 2 (metastatic)	64% (9)
		IGCCCG <sup>a</sup> - Good	89% (8)
		IGCCCG - Intermediate	11% (1)
	mGCT	Stage 1 (localised)	90% (9)
		LVI -	67% (6)
		LVI +	33% (3)
Stage 2 (metastatic)		10% (1)	
	IGCCCG - Good	100% (1)	
<b>Treatment</b>	Seminoma	1 x Carboplatin AUC7	81% (39)
		3/4 x EP120	17% (8)
		Radiotherapy	2% (1)
	NSGCTT	1 x BEP165	21% (3)
		2 x BEP120	21% (3)
		3/4 x BEP165	58% (8)
	mGCT	1 x BEP165	20% (2)
		2 x BEP120	60% (6)
		3 x BEP165	10% (1)
		Surveillance	10% (1)
<b>Recurrence within 2 years</b>		3% (2/72) patients	
<b>Age</b>		Median years (Range)	
	All TGCT patients	37 (20 - 57)	
	Seminoma	41 (21 - 57)	
	NSGCTT	25 (20 - 36)	
	mGCT	40 (30 - 48)	
Healthy donors	30 (23 -51)		

Abbreviations: LVI, Lymphovascular invasion; IGCCCG, International Germ Cell Cancer Collaborative Group; BEP, Bleomycin- Etoposide-Cisplatin; EP Etoposide-Cisplatin

<sup>a</sup>Prognostic classification of metastatic germ cell tumours